WACKER Will Not Produce an mRNA Vaccine for CureVac
CureVac N.V., a company based in Tübingen, Germany, needs less production capacity for CVnCOV, its mRNA vaccine candidate against Covid-19. As a result, it has terminated its contract with Wacker Chemie AG.
This will not have any significant impact on WACKER BIOSOLUTIONS’ sales and earnings in 2021. “And it does not change our medium-term targets for the Biosolutions division either,” said Dr. Susanne Leonhartsberger, the division’s head. “We are confident that we can provide other customers with the freed-up capacity for their mRNA and other molecules in the future,” added Dr. Susanne Leonhartsberger. WACKER’s site in Amsterdam has manufactured vaccines for customers for more than 20 years.
------
WACKER is a technological leader in the chemical industry and manufactures products for all key global industries. It is active in the silicone, polymer, life sciences and polysilicon markets.
( Press Release Image: https://photos.webwire.com/prmedia/6/279042/279042-1.jpg )
WebWireID279042
This news content was configured by WebWire editorial staff. Linking is permitted.
News Release Distribution and Press Release Distribution Services Provided by WebWire.